CLNN - Clene Inc.
IEX Last Trade
5.115
0 0%
Share volume: 5
Last Updated: Thu 26 Dec 2024 03:49:48 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$5.12
0.00
0.00%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
5.93%
1 Month
28.87%
3 Months
9.41%
6 Months
1,328.57%
1 Year
1,714.88%
2 Year
395.05%
Key data
Stock price
$5.12
DAY RANGE
$5.12 - $5.12
52 WEEK RANGE
$0.29 - $6.96
52 WEEK CHANGE
$1,685.71
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Robert D. Etherington
Region: US
Website: clene.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: clene.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Clene Inc. focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis. The company also markets and distributes dietary supplements.
Recent news